ACE2 and infection: Antiviral activity was initially assessed utilizing a plaque reduction assay (PRA) from culture supernatants harvested at 48 h postinfection (hpi) from A549-ACE2-TMPRSS2 cultures infected with variants at a multiplicity of infection (MOI) of 0.1.